Department of Cardiology VU University Medical Centre Amsterdam The Netherlands.
Department of Medical Biochemistry Academic Medical Centre Amsterdam The Netherlands.
J Am Heart Assoc. 2019 Oct 15;8(20):e012806. doi: 10.1161/JAHA.119.012806. Epub 2019 Oct 9.
Background In the presence of arterial stenosis, collateral artery growth (arteriogenesis) can alleviate ischemia and preserve tissue function. In patients with poorly developed collateral arteries, Gal-2 (galectin 2) expression is increased. In vivo administration of Gal-2 inhibits arteriogenesis. Blocking of Gal-2 potentially stimulates arteriogenesis. This study aims to investigate the effect of Gal-2 inhibition on arteriogenesis and macrophage polarization using specific single-domain antibodies. Methods and Results Llamas were immunized with Gal-2 to develop anti-Gal-2 antibodies. Binding of Gal-2 to monocytes and binding inhibition of antibodies were quantified. To test arteriogenesis in vivo, Western diet-fed LDLR.(low-density lipoprotein receptor)-null Leiden mice underwent femoral artery ligation and received treatment with llama antibodies 2H8 or 2C10 or with vehicle. Perfusion restoration was measured with laser Doppler imaging. In the hind limb, arterioles and macrophage subtypes were characterized by histology, together with aortic atherosclerosis. Llama-derived antibodies 2H8 and 2C10 strongly inhibited the binding of Gal-2 to monocytes (93% and 99%, respectively). Treatment with these antibodies significantly increased perfusion restoration at 14 days (relative to sham, vehicle: 41.3±2.7%; 2H8: 53.1±3.4%, =0.016; 2C10: 52.0±3.8%, =0.049). In mice treated with 2H8 or 2C10, the mean arteriolar diameter was larger compared with control (vehicle: 17.25±4.97 μm; 2H8: 17.71±5.01 μm; 2C10: 17.84±4.98 μm; <0.001). Perivascular macrophages showed a higher fraction of the M2 phenotype in both antibody-treated animals (vehicle: 0.49±0.24; 2H8: 0.73±0.15, =0.007; 2C10: 0.75±0.18, =0.006). In vitro antibody treatment decreased the expression of M1-associated cytokines compared with control (<0.05 for each). Atherosclerotic lesion size was comparable between groups (overall =0.59). Conclusions Inhibition of Gal-2 induces a proarteriogenic M2 phenotype in macrophages, improves collateral artery growth, and increases perfusion restoration in a murine hind limb model.
在动脉狭窄的情况下,侧支动脉生长(动脉生成)可以减轻缺血并维持组织功能。在侧支动脉发育不良的患者中,Gal-2(半乳糖凝集素 2)的表达增加。体内给予 Gal-2 抑制动脉生成。阻断 Gal-2 可能会刺激动脉生成。本研究旨在使用特异性单域抗体研究 Gal-2 抑制对动脉生成和巨噬细胞极化的影响。
用 Gal-2 免疫羊驼以开发抗 Gal-2 抗体。定量测定 Gal-2 与单核细胞的结合以及抗体的结合抑制。为了在体内测试动脉生成,接受西方饮食喂养的 LDLR(低密度脂蛋白受体)-null Leiden 小鼠进行股动脉结扎,并接受 llama 抗体 2H8 或 2C10 或载体治疗。用激光多普勒成像测量灌注恢复。在下肢中,通过组织学特征以及主动脉粥样硬化来描述小动脉和巨噬细胞亚型。来源于羊驼的抗体 2H8 和 2C10 强烈抑制 Gal-2 与单核细胞的结合(分别为 93%和 99%)。与假手术相比,用这些抗体治疗显着增加了 14 天时的灌注恢复(载体:41.3±2.7%;2H8:53.1±3.4%,=0.016;2C10:52.0±3.8%,=0.049)。用 2H8 或 2C10 治疗的小鼠与对照组相比,平均小动脉直径更大(载体:17.25±4.97μm;2H8:17.71±5.01μm;2C10:17.84±4.98μm;<0.001)。两种抗体处理的动物的血管周巨噬细胞均表现出更高比例的 M2 表型(载体:0.49±0.24;2H8:0.73±0.15,=0.007;2C10:0.75±0.18,=0.006)。与对照组相比,体外抗体治疗降低了 M1 相关细胞因子的表达(每种细胞因子<0.05)。各组之间的动脉粥样硬化病变大小无差异(总=0.59)。
Gal-2 抑制可诱导巨噬细胞中促动脉生成的 M2 表型,改善侧支动脉生长,并增加小鼠后肢模型中的灌注恢复。